Alpha Teknova (TKNO) Price & Analysis

Compare

280 Followers

TKNO Stock Chart & Stats

$2.25

-$0.21(-2.33%)

At close: Jan 08 4:00 PM EST

$2.25

-$0.21(-2.33%)

Day’s Range― - ―

52-Week Range$1.91 - $7.48

Previous CloseN/A

Volume51.57K

Average Volume (3M)318.88K

Market Cap

$127.40M

Enterprise Value$136.63M

Total Cash (Recent Filing)$5.91M

Total Debt (Recent Filing)$15.15M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

May 13, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding53,529,175

10 Day Avg. Volume259,294

30 Day Avg. Volume318,881

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)2.96

Price to Sales (P/S)5.02

P/FCF Ratio-22.01

Enterprise Value/Market Cap1.07

Enterprise Value/Revenue3.37

Enterprise Value/Gross Profit10.17

Enterprise Value/Ebitda-12.85

Forecast

1Y Price Target

$7.00

Price Target Upside211.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.32

Revenue Forecast (FY)$44.07M

Bulls Say, Bears Say

Bulls Say

Margin ImprovementAnalyst notes strength in the Clinical Solutions segment lifted overall profit margins, improving adjusted EBITDA prospects through better operational leverage.

Revenue GrowthAnalyst highlights consistent revenue growth across consecutive quarters, indicating improving core demand that could drive accelerating top-line momentum.

Sales And Marketing InvestmentAnalyst points out management's increased sales and marketing investment to capture rising biotech funding and emerging growth segments, which could amplify revenue recovery.

Bears Say

Customer Spending DeclineLab Essentials revenue was flat as more customers were offset by lower spending per customer, signaling limited upside from existing accounts and potential pressure on recurring revenue.

Segment WeaknessFlat Lab Essentials sales indicate uneven performance within the business, which could limit consolidated revenue growth despite gains elsewhere.

Alpha Teknova News

Alpha Teknova reports Q4 EPS (9c) vs. (11c) last year

Reports Q4 revenue $9.98M, consensus $9.61M. “After another successful year of disciplined execution against our strategic objectives, we’ve...

5d ago

TKNO

Alpha Teknova sees FY26 revenue $42M-$44M, consensus $44.12M

The company said, “Teknova anticipates total revenue of $42 million to $44 million for the fiscal year ending...

5d ago

TKNO

Teknova: Sustained Revenue Momentum, Margin Expansion, and Discounted Valuation Support Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on TKNO stock, giving a Buy rating yesterday....

4d ago

TKNO

Alpha Teknova Earnings Call: Mixed Outlook with Strategic Growth

Alpha Teknova, Inc. (($TKNO)) has held its Q3 earnings call. Read on for the main highlights of the...

4M ago

TKNO

Positive Outlook for Alpha Teknova: Consistent Revenue Growth and Strategic Expense Management Drive Buy Rating

William Blair analyst Matt Larew has reiterated their bullish stance on TKNO stock, giving a Buy rating yesterday....

4M ago

TKNO

Alpha Teknova Reports Strong Q3 2025 Growth

Alpha Teknova, Inc. ( ($TKNO) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

TKNO

Alpha Teknova’s Strong Performance and Growth Potential Justifies Buy Rating Despite Market Adjustments

Alpha Teknova, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith from...

4M ago

TKNO

Alpha Teknova backs FY25 revenue view $39M-$42M, consensus $40.61M

The company said, “Teknova reiterates its fiscal 2025 outlook for revenue and Free Cash Outflow. The Company continues...

4M ago

TKNO

Alpha Teknova reports Q3 EPS (8c), consensus (9c)

Reports Q3 revenue $10.45M, consensus $10.23M. “We had a strong third quarter, our fifth consecutive quarter of year-over-year...

4M ago

TKNO

Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks

The stock market’s largest players – companies like Nvidia and its trillion-dollar peers – often dominate the headlines...

5M ago

TARA

TKNO

Alpha Teknova: Solid Q2 Performance but Modest Growth Outlook and High Valuation Justify Hold Rating

BTIG analyst Mark Massaro has reiterated their neutral stance on TKNO stock, giving a Hold rating yesterday. Mark...

7M ago

TKNO

new option listings on August 14th

New option listings for August 14th include ALTiGlobal, Inc. (ALTI), Advanced Technologies Group Ltd (AVGG), Connecticut River Community...

7M ago

MFH

ALTI

Alpha Teknova’s Earnings Call: Growth Amid Challenges

Alpha Teknova, Inc. (($TKNO)) has held its Q2 earnings call. Read on for the main highlights of the...

7M ago

TKNO

Teknova’s Strong Execution and Financial Progress Justify Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on TKNO stock, giving a Buy rating today....

7M ago

TKNO

TKNO FAQ

What was Alpha Teknova’s price range in the past 12 months?

Alpha Teknova lowest stock price was $1.91 and its highest was $7.48 in the past 12 months.

What is Alpha Teknova’s market cap?

Alpha Teknova’s market cap is $127.40M.

When is Alpha Teknova’s upcoming earnings report date?

Alpha Teknova’s upcoming earnings report date is May 13, 2026 which is in 71 days.

How were Alpha Teknova’s earnings last quarter?

Alpha Teknova released its earnings results on Feb 26, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.003.

Is Alpha Teknova overvalued?

According to Wall Street analysts Alpha Teknova’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alpha Teknova pay dividends?

Alpha Teknova does not currently pay dividends.

What is Alpha Teknova’s EPS estimate?

Alpha Teknova’s EPS estimate is -0.09.

How many shares outstanding does Alpha Teknova have?

Alpha Teknova has 53,529,175 shares outstanding.

What happened to Alpha Teknova’s price movement after its last earnings report?

Alpha Teknova reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went up 13.158%.

Which hedge fund is a major shareholder of Alpha Teknova?

Currently, no hedge funds are holding shares in TKNO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alpha Teknova Stock Smart Score

Underperform

Fundamentals

Return on Equity

-22.79%

Trailing 12-Months

Asset Growth

-4.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alpha Teknova

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Alpha Teknova (TKNO) Earnings & Revenues

Historic Earnings Reports

TKNO Company Deck

TKNO Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call portrayed clear operational and financial progress: revenue growth (6th straight quarter), improved gross margins, narrower net losses and adjusted EBITDA, better free cash flow performance, growing clinical customer count and pipeline progress. Management is beginning to reinvest (~$2M) in commercial capabilities, providing a plausible path to adjusted EBITDA positivity by end of 2027 (targeting $52M–$57M annualized revenue). Key near-term risks include ongoing negative adjusted EBITDA and free cash outflow, lowered average revenue per customer from new/early-stage accounts, revenue lumpiness in Clinical Solutions, and reliance on a sustained biotech funding recovery (with a ~4-quarter lag) to accelerate revenue. Overall, the company is trending in the right direction but still requires execution and favorable market conditions to meet longer-term targets.View all TKNO earnings summaries

TKNO Stock 12 Month Forecast

Average Price Target

$7.00

▲(211.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","9":"$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.37,2.726153846153846,3.082307692307692,3.4384615384615387,3.7946153846153847,4.150769230769231,4.506923076923077,4.863076923076923,5.219230769230769,5.575384615384616,5.931538461538461,6.287692307692308,6.643846153846154,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.37,2.726153846153846,3.082307692307692,3.4384615384615387,3.7946153846153847,4.150769230769231,4.506923076923077,4.863076923076923,5.219230769230769,5.575384615384616,5.931538461538461,6.287692307692308,6.643846153846154,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.37,2.726153846153846,3.082307692307692,3.4384615384615387,3.7946153846153847,4.150769230769231,4.506923076923077,4.863076923076923,5.219230769230769,5.575384615384616,5.931538461538461,6.287692307692308,6.643846153846154,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.19,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 64, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >